Tsveta Milanova Net Worth

The estimated Net Worth of Tsveta Milanova is at least $658 ezer dollars as of 20 January 2024. Tsveta Milanova owns over 5,448 units of Agios Pharmaceuticals Inc stock worth over $658,092 and over the last 2 years Tsveta sold AGIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Tsveta Milanova AGIO stock SEC Form 4 insiders trading

Tsveta has made over 3 trades of the Agios Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Tsveta exercised 5,448 units of AGIO stock worth $241,401 on 20 January 2024.

The largest trade Tsveta's ever made was exercising 8,475 units of Agios Pharmaceuticals Inc stock on 3 January 2024 worth over $375,527. On average, Tsveta trades about 3,874 units every 41 days since 2023. As of 20 January 2024 Tsveta still owns at least 14,852 units of Agios Pharmaceuticals Inc stock.

You can see the complete history of Tsveta Milanova stock trades at the bottom of the page.

What's Tsveta Milanova's mailing address?

Tsveta's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Agios Pharmaceuticals Inc

Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen és John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.

What does Agios Pharmaceuticals Inc do?

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible

Complete history of Tsveta Milanova stock trades at Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc executives and stock owners

Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jacqualyn Fouse,
  Chief Executive Officer, Director
• Christopher Bowden,
  Chief Medical Officer
• Jonathan Biller,
  Chief Financial Officer, Head of Legal and Corporate Affairs
• David Schenkein,
  Executive Chairman of the Board
• Dr. Sarah Gheuens M.D., Ph.D.,
  Chief Medical Officer
• Dr. Jacqualyn A. Fouse,
  CEO & Director
• Dr. Bruce Car Ph.D.,
  Chief Scientific Officer
• Jonathan Biller J.D.,
  CFO & Head of Corp. Affairs
• Richa Poddar,
  Chief Commercial Officer
• John Maraganore,
  Independent Director
• Kaye Foster,
  Independent Director
• Paul Clancy,
  Independent Director
• Maykin Ho,
  Independent Director
• David Scadden,
  Director
• Ian Clark,
  Independent Director
• Holly Manning,
  IR Contact Officer
• Bruce Car,
  Chief Scientific Officer
• Dr. Craig B. Thompson M.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Kendra Adams,
  VP of External Communications & Investor Relations
• Dr. Clive Patience Ph.D.,
  Chief Technical Operations Officer
• T. J. Washburn Jr.,
  Principal Accounting Officer
• Dr. Shin-San Su Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Craig B. Thompson,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Tak Wah Mak,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Lewis Clayton Cantley Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Lewis Clayton Jr. Cantley,
  Director
• Carman Alenson,
  Principal Accounting Officer
• Scott Biller,
  Chief Scientific Officer
• Douglas G. Cole,
  Director
• Steven L. Hoerter,
  Chief Commercial Officer
• Marc Tessier Lavigne,
  Director
• Robert Nelsen,
  Director
• European Investment Co Llc ...,
  
• Corp /De/Celgene Switzerlan...,
  
• Sarah Gheuens,
  Chief Medical Officer
• Ventures Fund 2007, L.P.Afe...,
  
• Venture Fund Vii Lparch Ven...,
  
• European Investment Co Llc ...,
  10% owner
• European Investment Co Llcc...,
  
• Rock Ventures Lp Third Rock...,
  
• Kevin P Starr,
  Director
• Glenn Goddard,
  Senior Vice President, Finance
• John Duncan Higgons,
  Chief Operating Officer
• Venture Fund Vii Lparch Ven...,
  
• Perry A Karsen,
  Director
• Corp /De/Celgene European I...,
  
• Catherine E. Owen,
  Director
• Cecilia Jones,
  Chief Financial Officer
• Theodore James Jr. Washburn,
  Principal Accounting Officer
• Darrin Miles,
  Chief Commercial Officer
• Richa Poddar,
  Chief Commercial Officer
• James William Burns,
  Chief Legal Officer
• Brian Goff,
  Chief Executive Officer
• Rahul D. Ballal,
  Director
• Cynthia Smith,
  Director
• Tsveta Milanova,
  Chief Commercial Officer
• Jeffrey D Capello,
  Director